Clinical Edge Journal Scan

Gastric cancer: Epstein-Barr virus and H. pylori coinfection is not prognostic


 

Key clinical point: Epstein-Barr virus (EBV) and Helicobacter pylori coinfection is not an independent prognostic factor for gastric cancer. EBV infection was associated with survival, but not in patients with non-gastric carcinoma with lymphoid stroma (non-GCLS).

Major finding: EBV infection alone (hazard ratio 0.362; P = .049) showed an inverse correlation with overall survival (OS). The 5-year OS rate was not significantly different between the EBV and H. pylori coinfection vs. other groups (97.6% vs. 86.8%; P = .144). In patients with non-GCLS, the OS rate was not significantly different between the EBV-positive vs. other groups (96.9% vs. 86.4%; P = .126).

Study details: This retrospective study included 956 patients with gastric cancer who underwent surgery between September 2014 and August 2015 and were subdivided into groups according to the GCLS morphology and EBV and H. pylori infection statuses.

Disclosures: No funding source was identified for this study. Dr. JY Ahn is an editorial board member of the journal. The other authors reported no conflicts of interest.

Source: Noh JH et al. Clinical significance of Epstein-Barr virus and Helicobacter pylori infection in gastric carcinoma. Gut Liver. 2022 (May 25). Doi: 10.5009/gnl210593

Recommended Reading

Refractory metastatic CRC: Raltitrexed plus S-1 betters regorafenib in prolonging survival
MDedge Hematology and Oncology
CRC with synchronous liver metastases: Outcomes of simultaneous laparoscopic vs. hybrid and open resection
MDedge Hematology and Oncology
Does high consumption of nuts and legumes protect against CRC?
MDedge Hematology and Oncology
Obesity and metabolic syndrome at younger ages may increase earlier-onset CRC risk
MDedge Hematology and Oncology
Multi-agent vs. single-agent adjuvant chemotherapy in elderly patients with stage III colon cancer
MDedge Hematology and Oncology
Advanced gastric cancer: Ramucirumab-irinotecan combo fails phase 2
MDedge Hematology and Oncology
Gastric cancer: Tumor mutational burden and outcomes with pembrolizumab
MDedge Hematology and Oncology
Is there a link between tea consumption and gastric cancer?
MDedge Hematology and Oncology
Metastatic gastric cancer: CD163+ macrophage infiltration is a prognostic biomarker
MDedge Hematology and Oncology
Gastric cancer: What is the optimal surgical strategy in the elderly?
MDedge Hematology and Oncology